225 related articles for article (PubMed ID: 35242632)
1. Use of on-therapy ctDNA monitoring in a patient with
Yeung V; Kim C; Kiedrowski LA; Liu SV; Reuss JE
Transl Lung Cancer Res; 2022 Jan; 11(1):111-116. PubMed ID: 35242632
[TBL] [Abstract][Full Text] [Related]
2. Targeted treatments after chemoradiotherapy failure in a patient with relapsed, advanced non‑small cell lung cancer with on‑therapy circulating tumor biomarker monitoring: A case report.
Bi Y; Xia C; Zhang X; Liu H
Oncol Lett; 2023 Sep; 26(3):407. PubMed ID: 37600327
[TBL] [Abstract][Full Text] [Related]
3. Cell-free circulating tumor DNA supplementing tissue biopsies for identification of targetable mutations: Implications for precision medicine and considerations for reconciling results.
Hicks JK; Saller J; Wang E; Boyle T; Gray JE
Lung Cancer; 2017 Sep; 111():135-138. PubMed ID: 28838384
[TBL] [Abstract][Full Text] [Related]
4. Pralsetinib: A Review in Advanced RET Fusion-Positive NSCLC.
Syed YY
Drugs; 2022 May; 82(7):811-816. PubMed ID: 35587858
[TBL] [Abstract][Full Text] [Related]
5. The budget impact of adding pralsetinib to a US health plan formulary for treatment of non-small cell lung cancer and thyroid cancer with
Duff S; Bargiacchi F; Norregaard C; Brener M; Sullivan E
J Manag Care Spec Pharm; 2022 Feb; 28(2):218-231. PubMed ID: 34726500
[No Abstract] [Full Text] [Related]
6. Partial response to pralsetinib in an advanced pulmonary sarcomatoid carcinoma patient harboring a KIF5B-RET rearrangement: a case report.
Wu Y; Yan Z; Pan J; Chang X; Huang B; Luo D; Meng R; Shi H; Fan J; Nie X
World J Surg Oncol; 2022 Dec; 20(1):386. PubMed ID: 36471407
[TBL] [Abstract][Full Text] [Related]
7. The genomic characteristics of RET fusion positive tumors in Chinese non-small cell lung cancer (NSCLC) patients.
Wu G; Guo L; Gu Y; Huang T; Liu M; Zou X; Yang B; Huang P; Wen C; Yi L; Liao W; Zhao D; Zhu J; Zhang X; Liu Y; Yin Y; Chen S
J Cancer Res Clin Oncol; 2023 Mar; 149(3):1019-1028. PubMed ID: 35220468
[TBL] [Abstract][Full Text] [Related]
8. Pralsetinib for the treatment of a
Meng Y; Li L; Wang H; Chen X; Yue Y; Wang M; Meng L; Li B; Li X
Ann Transl Med; 2022 Apr; 10(8):496. PubMed ID: 35571397
[TBL] [Abstract][Full Text] [Related]
9. [Detection of novel driver mutations in liquid biopsy: case report of a RET-positive lung adenocarcinoma treated with pralsetinib.].
Russano M
Recenti Prog Med; 2021 Jan; 112(1):5e-9e. PubMed ID: 33512366
[TBL] [Abstract][Full Text] [Related]
10. High-dose alectinib for
Dziadziuszko R; Peled N; Mok T; Peters S; Aix SP; Alatorre-Alexander J; Vicuna BD; Maclennan M; Bhagawati-Prasad V; Shagan SM; Schleifman E; Ruf T; Mathisen MS; Gadgeel SM
Contemp Oncol (Pozn); 2023; 27(4):217-223. PubMed ID: 38405208
[TBL] [Abstract][Full Text] [Related]
11. KIF5B/RET fusion gene analysis in a selected series of cytological specimens of EGFR, KRAS and EML4-ALK wild-type adenocarcinomas of the lung.
Borrelli N; Giannini R; Proietti A; Alì G; Pelliccioni S; Niccoli C; Lucchi M; Melfi F; Mussi A; Basolo F; Fontanini G
Lung Cancer; 2013 Sep; 81(3):377-381. PubMed ID: 23891510
[TBL] [Abstract][Full Text] [Related]
12. Base-Position Error Rate Analysis of Next-Generation Sequencing Applied to Circulating Tumor DNA in Non-Small Cell Lung Cancer: A Prospective Study.
Pécuchet N; Zonta E; Didelot A; Combe P; Thibault C; Gibault L; Lours C; Rozenholc Y; Taly V; Laurent-Puig P; Blons H; Fabre E
PLoS Med; 2016 Dec; 13(12):e1002199. PubMed ID: 28027313
[TBL] [Abstract][Full Text] [Related]
13. Case report: Recurrent lung infections following treatment with pralsetinib for an elderly patient with
An L; Chen P; Wang J; Qin X; Liu T; Gao Y; Wang P; Zhang D; Fang X; Zhang Z
Front Oncol; 2022; 12():1024365. PubMed ID: 36568233
[TBL] [Abstract][Full Text] [Related]
14. Use of Pralsetinib as Neoadjuvant Therapy for Non-Small Cell Lung Cancer Patient With RET Rearrangement.
Zhou N; Li T; Liang M; Ren F; Ni H; Liu W; Shi T; Xu D; Chen Q; Yu H; Song Z; Zu L; Li S; Xu S
Front Oncol; 2022; 12():848779. PubMed ID: 35223529
[TBL] [Abstract][Full Text] [Related]
15. Association of Circulating Tumor DNA Testing Before Tissue Diagnosis With Time to Treatment Among Patients With Suspected Advanced Lung Cancer: The ACCELERATE Nonrandomized Clinical Trial.
García-Pardo M; Czarnecka-Kujawa K; Law JH; Salvarrey AM; Fernandes R; Fan ZJ; Waddell TK; Yasufuku K; Liu G; Donahoe LL; Pierre A; Le LW; Gunasegaran T; Ghumman N; Shepherd FA; Bradbury PA; Sacher AG; Schmid S; Corke L; Feng J; Stockley T; Pal P; Rogalla P; Pipinikas C; Howarth K; Ambasager B; Mezquita L; Tsao MS; Leighl NB
JAMA Netw Open; 2023 Jul; 6(7):e2325332. PubMed ID: 37490292
[TBL] [Abstract][Full Text] [Related]
16. Analysis of Cell-Free DNA from 32,989 Advanced Cancers Reveals Novel Co-occurring Activating
Rich TA; Reckamp KL; Chae YK; Doebele RC; Iams WT; Oh M; Raymond VM; Lanman RB; Riess JW; Stinchcombe TE; Subbiah V; Trevarthen DR; Fairclough S; Yen J; Gautschi O
Clin Cancer Res; 2019 Oct; 25(19):5832-5842. PubMed ID: 31300450
[TBL] [Abstract][Full Text] [Related]
17. Case Report: A case of ultra-late recurrence of
Park HY; Park JH; Shin MG; Han SJ; Ji YS; Oh HJ; Kim YC; Lee T; Choi YD; Oh IJ
Front Oncol; 2023; 13():1178762. PubMed ID: 37182165
[TBL] [Abstract][Full Text] [Related]
18. A Metastatic Pulmonary Sarcomatoid Carcinoma Patient Harboring
Qin H; Wan Y; Dong Y; Sun Q
Cancer Manag Res; 2023; 15():765-769. PubMed ID: 37525669
[TBL] [Abstract][Full Text] [Related]
19. Usefulness of Circulating Tumor DNA in Identifying Somatic Mutations and Tracking Tumor Evolution in Patients With Non-small Cell Lung Cancer.
Roosan MR; Mambetsariev I; Pharaon R; Fricke J; Husain H; Reckamp KL; Koczywas M; Massarelli E; Bild AH; Salgia R
Chest; 2021 Sep; 160(3):1095-1107. PubMed ID: 33878340
[TBL] [Abstract][Full Text] [Related]
20. Intracranial Activity of Selpercatinib in Chinese Patients With Advanced
Cheng Y; Huang D; Zhou J; Zhou C; Sun Y; Wu L; Guo Y; Jingxin S; Zhang W; Lu S
JCO Precis Oncol; 2023 Jun; 7():e2200708. PubMed ID: 37315261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
